

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroTech Limited

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

CHANGE OF DIRECTORS AND CHAIRMAN, CHANGE IN COMPOSITION OF BOARD COMMITTEE AND CHANGE OF AUTHORISED REPRESENTATIVE

The Board announces that, with effect from November 3, 2023:

- (1) Mr. Peng Bo has resigned as a non-executive Director, the Chairman, a member of the Remuneration Committee, Authorized Representative, and a director and the chairman of MicroPort NeuroTech due to retirement.
- (2) Dr. Chang Zhaohua has been appointed as a non-executive Director and the Chairman.
- (3) Mr. Xie Zhiyong has been appointed as a member of Remuneration Committee, Authorized Representative, and the chairman of MicroPort NeuroTech.
- (4) Mr. Sun Qingwei has been appointed as a non-executive Director and a director of MicroPort NeuroTech.

The Board would like to welcome Dr. Chang and Mr. Sun for joining as members of the Board, and believes that under the strategic guidance of the newly appointed Directors, the Company will usher in more substantial and steady development and progress.

Change of Directors and Chairman, Change in composition of Board Committee and Change of Authorised Representative

The Board announces that Mr. Peng Bo (彭博) (“**Mr. Peng**”) has resigned as a non-executive Director, the Chairman, a member of the Remuneration Committee, Authorized Representative, and a director and the chairman of MicroPort NeuroTech, with effect from November 3, 2023 due to retirement. Dr. Chang Zhaohua (常兆華) (“**Dr. Chang**”) has been appointed as a non-executive Director and the Chairman, with effect from the same date. Mr. Xie Zhiyong has been appointed as a member of Remuneration Committee, Authorized Representative, and the chairman of MicroPort NeuroTech, with effect from the same date. Mr. Sun Qingwei (孫慶蔚) (“**Mr. Sun**”) has been appointed as a non-executive Director and a director of MicroPort NeuroTech, with effect from the same date.

Mr. Peng has confirmed to the Company that he does not have any disagreement with the Board and that there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and/or the Stock Exchange.

Mr. Peng was diligent, responsible and dedicated during his tenure of office in the Company, and played positive roles in the standardised operation and healthy development of the Company. The Board would like to take this opportunity to express its sincere appreciation and gratitude to Mr. Peng for his remarkable and valuable contribution during his term of service.

Details of Dr. Chang

The biographical details of Dr. Chang are set out as follows:

Dr. Chang, born in 1963, is the current chairman of the board of directors, executive director and chief executive officer of MicroPort. He has over 32 years' experience in the medical device industry, and currently also serve as a professor at School of Medical Device, University of Shanghai for Science and Technology. Before establishing Shanghai MicroPort Medical (Group) Co., Ltd. (上海微創醫療器械 (集團) 有限公司) in 1998, from 1996 to 1997, Dr. Chang served as vice president of R&D at Endocare Inc., a NASDAQ listed medical device company based in California, U.S.. From 1990 to 1995, Dr. Chang served as senior engineer, chief scientist, director of R&D and vice president of engineering at Cryomedical Sciences Inc., a medical device company in Maryland U.S. which was listed on NASDAQ prior to its acquisition by a third party. Dr. Chang received his bachelor's degree in refrigeration engineering in 1983 and master's degree in cryogenic engineering in 1985, both from University of Shanghai for Science and Technology. In 1992, he received his doctoral degree in biological science from State University of New York (Binghamton). Dr. Chang has published extensively in biomedical fields and holds several dozens of patents in China and the United States.

Dr. Chang shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.

Dr. Chang has entered into an appointment letter with the Company. The initial term of his appointment letter shall commence from the date of the appointment as a non-executive Director and continue for a period of three years, and shall be subject to re-election as and when required under the articles of association of the Company and the Listing Rules, until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than 30 days' prior notice in writing. Pursuant to his letter of appointment, he is not entitled to receive director's fee from the Company. Dr. Chang's remuneration will be subject to annual review by the Remuneration Committee and the Board from time to time with reference to the Company's remuneration policy, the prevailing market level and his responsibilities and performance.

As of the date of this announcement, save as Dr. Chang's interest in 49,047,671 underlying shares of MicroPort and 6,000,000 underlying shares of MicroPort CardioFlow Medtech Corporation, he does not have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO (Chapter 571 of the Laws of Hong Kong).

Dr. Chang confirms that save as disclosed above, as of the date of this announcement, he does not (i) hold any other position in the Company or its major subsidiaries nor any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under the Listing Rules) of the Company; and (iii) have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (within the meaning of Part XV of the SFO)(Chapter 571 of the Laws of Hong Kong) of the Company or its associated corporations.

Save as disclosed above, the Board is not aware of any other information which is discloseable pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter relating to the appointment of Dr. Chang that need to be brought to the attention of the shareholders of the Company.

Details of Mr. Sun

The biographical details of Mr. Sun are set out as follows:

Mr. Sun, born in 1983, joined MicroPort in October 2018 and has held various positions including assistant to the CEO and senior director of strategy and planning. During that period, he was responsible for the strategic planning and operation of the company, leading the strategic layout and assisting dozens of MicroPort's subsidiaries to establish medium to long-term development plans. He has also pioneered a number of emerging areas and led the start-up development of new businesses. Prior to joining MicroPort, Mr. Sun accumulated many years of experience in pharmaceutical and life science consulting in Boston, U.S., where he conducted in-depth research in the areas of biopharmaceuticals, medical devices, diagnostics, and healthcare services. Mr. Sun graduated from Kyoto University of Japan in 2007 with a bachelor's degree in engineering science, majoring in materials science and engineering, and obtained a master's degree in materials engineering from Kyoto University of Japan in 2009. Mr. Sun attended Harvard School of Public Health since 2009 and obtained a master's degree in environmental health in 2011.

Mr. Sun shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.

Mr. Sun has entered into an appointment letter with the Company. The initial term of his appointment letter shall commence from the date of the appointment as a non-executive Director and continue for a period of three years, and shall be subject to re-election as and when required under the articles of association of the Company and the Listing Rules, until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than 30 days' prior notice in writing. Pursuant to his letter of appointment, he is not entitled to receive director's fee from the Company. Mr. Sun's remuneration will be subject to annual review by the Remuneration Committee and the Board from time to time with reference to the Company's remuneration policy, the prevailing market level and his responsibilities and performance.

As of the date of this announcement, save as Mr. Sun's interest in 259,848 underlying shares of MicroPort and 39,177 shares of the Company, he does not have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO (Chapter 571 of the Laws of Hong Kong).

Mr. Sun confirms that save as disclosed above, as of the date of this announcement, he does not (i) hold any other position in the Company or its major subsidiaries nor any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under the Listing Rules) of the Company; and (iii) have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (within the meaning of Part XV of the SFO) (Chapter 571 of the Laws of Hong Kong) of the Company or its associated corporations.

Save as disclosed above, the Board is not aware of any other information which is discloseable pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter relating to the appointment of Mr. Sun that need to be brought to the attention of the shareholders of the Company.

The Board would like to welcome Dr. Chang and Mr. Sun for joining as a member of the Board, and believes that under the strategic guidance of the newly appointed Directors, the Company will usher in more substantial and steady development and progress.

DEFINITION

“Audited Committee”	the audited committee of our Company
“Authorized Representative”	the authorized representative of the Company for the purpose of Rule 3.05 of the Listing Rules
“Board”	the board of directors of our Company
“Chairman”	the chairman of the Board
“China” or “PRC”	People’s Republic of China
“Company”	MicroPort NeuroTech Limited (微創腦科學有限公司), an exempted company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 2172)
“Director(s)”	the director(s) of our Company, including all executive, non-executive and independent non-executive directors
“Group” or “our Group”	the Company and all of our subsidiaries or, where the context so requires, in respect of the period before the Company became the holding company of its present subsidiaries, the present subsidiaries of the Company and the businesses operated by such subsidiaries or their predecessors (as the case may be)
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time
“MicroPort”	MicroPort Scientific Corporation (微創醫療科學有限公司), an exempted company incorporated in the Cayman Islands with limited liability and the shares of which are listed on the main board of the Stock Exchange (stock code: 00853), and a controlling shareholder of the Company

“MicroPort NeuroTech”	MicroPort NeuroTech (Shanghai) Co., Ltd (微創神通醫療科技(上海)有限公司), a company established in the PRC with limited liability on 16 May 2012, and an indirectly wholly-owned subsidiary of the Company
“Remuneration Committee”	the remuneration committee of the Company
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Stock Exchange”	The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
“United States” or “U.S.”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction

By order of the Board
MicroPort NeuroTech Limited
Dr. Chang Zhaohua
Chairman

Hong Kong, November 3, 2023

As at the date of this announcement, the executive Directors are Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce, the non-executive Directors are Dr. Chang Zhaohua, Mr. Sun Qingwei, Mr. Wang Lin and Ms. Wu Xia, and the independent non-executive Directors are Dr. Xu Yi, Dr. Zhang Haixiao and Mr. Siu Chi Hung.